CN116622572A - 抑制幽门螺杆菌的动物双歧杆菌乳亚种atm-209及其应用 - Google Patents
抑制幽门螺杆菌的动物双歧杆菌乳亚种atm-209及其应用 Download PDFInfo
- Publication number
- CN116622572A CN116622572A CN202310578935.7A CN202310578935A CN116622572A CN 116622572 A CN116622572 A CN 116622572A CN 202310578935 A CN202310578935 A CN 202310578935A CN 116622572 A CN116622572 A CN 116622572A
- Authority
- CN
- China
- Prior art keywords
- bifidobacterium animalis
- helicobacter pylori
- atm
- lactis
- animalis subspecies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000590002 Helicobacter pylori Species 0.000 title claims abstract description 39
- 229940037467 helicobacter pylori Drugs 0.000 title claims abstract description 39
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 15
- 241001134770 Bifidobacterium animalis Species 0.000 title claims description 66
- 229940118852 bifidobacterium animalis Drugs 0.000 title claims description 66
- 206010019375 Helicobacter infections Diseases 0.000 claims abstract description 24
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 17
- 235000013305 food Nutrition 0.000 claims abstract description 15
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 206010061218 Inflammation Diseases 0.000 claims abstract description 11
- 230000004054 inflammatory process Effects 0.000 claims abstract description 11
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
- 230000002265 prevention Effects 0.000 claims abstract description 7
- 238000009629 microbiological culture Methods 0.000 claims abstract description 3
- 238000004321 preservation Methods 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims description 36
- 230000000813 microbial effect Effects 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 abstract description 20
- 230000002496 gastric effect Effects 0.000 abstract description 19
- 241001465754 Metazoa Species 0.000 abstract description 13
- 241000186000 Bifidobacterium Species 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 8
- 230000005764 inhibitory process Effects 0.000 abstract description 6
- 239000002253 acid Substances 0.000 abstract description 5
- 230000009036 growth inhibition Effects 0.000 abstract description 5
- 238000001727 in vivo Methods 0.000 abstract description 5
- 244000005700 microbiome Species 0.000 abstract description 2
- 239000006041 probiotic Substances 0.000 description 18
- 235000018291 probiotics Nutrition 0.000 description 18
- 239000001963 growth medium Substances 0.000 description 15
- 229940079593 drug Drugs 0.000 description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 230000003115 biocidal effect Effects 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 230000001580 bacterial effect Effects 0.000 description 12
- 210000004211 gastric acid Anatomy 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 210000004400 mucous membrane Anatomy 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000000529 probiotic effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 108010046334 Urease Proteins 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 239000004310 lactic acid Substances 0.000 description 7
- 235000014655 lactic acid Nutrition 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 102000004889 Interleukin-6 Human genes 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- 102000004890 Interleukin-8 Human genes 0.000 description 6
- 108090001007 Interleukin-8 Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 6
- 241000699694 Gerbillinae Species 0.000 description 5
- 229940009289 bifidobacterium lactis Drugs 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000011556 gerbil model Methods 0.000 description 4
- 229940100601 interleukin-6 Drugs 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 210000004876 tela submucosa Anatomy 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 208000007882 Gastritis Diseases 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 238000000184 acid digestion Methods 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 229910001961 silver nitrate Inorganic materials 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000011632 Caseins Human genes 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241001168604 Helicobacter pylori NCTC 11639 Species 0.000 description 2
- 241000194036 Lactococcus Species 0.000 description 2
- 241000192132 Leuconostoc Species 0.000 description 2
- 201000003791 MALT lymphoma Diseases 0.000 description 2
- 241000192001 Pediococcus Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229910052797 bismuth Inorganic materials 0.000 description 2
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 235000021107 fermented food Nutrition 0.000 description 2
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 2
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- CDUFCUKTJFSWPL-UHFFFAOYSA-L manganese(II) sulfate tetrahydrate Chemical compound O.O.O.O.[Mn+2].[O-]S([O-])(=O)=O CDUFCUKTJFSWPL-UHFFFAOYSA-L 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002985 plastic film Substances 0.000 description 2
- 229920006255 plastic film Polymers 0.000 description 2
- 235000021108 sauerkraut Nutrition 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000699684 Meriones unguiculatus Species 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 235000005118 dietary health Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 231100000003 human carcinogen Toxicity 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229940068140 lactobacillus bifidus Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003110 molding sand Substances 0.000 description 1
- 238000011586 mongolian gerbil model Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 239000001393 triammonium citrate Substances 0.000 description 1
- 235000011046 triammonium citrate Nutrition 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明涉及微生物技术领域,具体涉及抑制幽门螺杆菌的动物双歧杆菌乳亚种ATM‑209及其应用。本发明提供的动物双歧杆菌乳亚种(Bifidobacterium animalis subsp.lactis)ATM‑209(GOLDGUT‑BB18)保藏于中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为CGMCC No.25896。该菌株具有较好的耐酸能力,可很好地适应于胃部环境;该菌株对幽门螺杆菌具有明显的生长抑制作用,在动物实验中能够抑制幽门螺杆菌在体内的定植并缓解幽门螺杆菌感染所造成的炎症,在临床预防、治疗和抑制幽门螺杆菌感染相关病症以及胃肠道保健食品等领域具有广阔的应用前景。
Description
技术领域
本发明涉及微生物技术领域,尤其涉及抑制幽门螺杆菌的动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)及其应用。
背景技术
幽门螺杆菌(Helicobacter Pylori,Hp)是一种螺旋弯曲、有鞭毛、微好氧的革兰氏阴性菌。幽门螺杆菌感染是人类最普遍的慢性细菌性疾病之一。幽门螺杆菌也是世界卫生组织(WHO)和国际癌症研究机构(IARC)认定的一级人类致癌物。幽门螺杆菌在胃部感染并定植时,会分泌大量尿素酶将胃粘液中的尿素转化为氨以中和胃酸,避免受胃酸影响,进而使其在胃与十二指肠中大量增殖,破坏胃粘膜屏障,诱导胃粘膜细胞凋亡,导致组织损伤和溃疡形成。因此幽门螺杆菌感染与胃肠道恶性及非恶性疾病有关,如胃炎(gastritis)、慢性消化不良、粘膜相关淋巴组织淋巴癌(mucosa-associated lymphoid tissuelymphoma)以及胃腺癌(gastric adenocarcinoma)等。胃癌最常见的原因是幽门螺杆菌感染,因此抑制幽门螺杆菌感染是预防胃癌最有效的方法。
幽门螺杆菌感染的治疗通常会使用3或4种不同的药物或抗生素以获得足够的根除率。近年来,由于越来越多幽门螺杆菌菌株对抗生素的耐药性增加,许多治疗方案的有效性也在下降,而且某些抗生素可能会引起更多的副作用与不良反应。因此,本领域的相关研究人员致力于探究有效且不产生副作用的治疗方法,如使用益生菌(probiotics)结合抗生素来治疗或根除幽门螺杆菌感染,其中益生菌可以减少抗生素的耐药性,并具有平衡肠道菌群,改善肠道微生态的作用。
乳酸菌(lactic acid bacteria,LAB)属于一般被公认为安全(generallyrecognized as safe,GRAS)且广泛应用于医药、食品等行业的益生菌。乳酸菌能够将碳水化合物发酵成乳酸,可用于制造酸奶、奶酪、酸菜、啤酒、葡萄酒、泡菜、腌渍食品和其他发酵食品。常见的乳酸菌属包括:乳杆菌属(Lactobacillus)、双歧杆菌属(Bifidobacterium)、乳球菌属(Lactococcus)、链球菌属(Streptococcus)、片球菌属(Pediococcus)以及明串珠菌属(Leuconostoc)等。乳酸菌可以对人类宿主产生较多的有益作用,包括抗过敏作用、抗菌作用、调节肠道微生物菌群、刺激免疫***和预防结肠癌等,且已有一些关于乳酸菌菌株在抗幽门螺杆菌上的应用研究。
为了更好地满足临床实践需求,需要开发多样化和有效的益生菌来抑制和治疗幽门螺杆菌相关感染疾病。
发明内容
本发明提供抑制幽门螺杆菌的动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)及其应用。
本发明提供动物双歧杆菌乳亚种(Bifidobacterium animalis subsp.lactis)ATM-209(GOLDGUT-BB18),该菌株于2022年10月12日保藏于中国微生物菌种保藏管理委员会普通微生物中心(简称CGMCC,地址:北京市朝阳区北辰西路1号院3号,中国科学院微生物研究所,邮编100101),分类命名为动物双歧杆菌乳亚种Bifidobacterium animalissubsp.lactis,保藏编号为CGMCC No.25896。
动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)分离自健康婴儿粪便。通过细菌形态学、生理学以及16S rDNA(SEQ ID NO.1)测序对该菌株进行鉴定,结果为动物双歧杆菌乳亚种(Bifidobacterium animalis subsp.lactis),命名为动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)。该菌株具有较好的耐胃酸能力,对幽门螺杆菌有明显的生长抑制作用,在动物实验中能够显著降低胃部幽门螺杆菌载量并缓解致病菌感染所造成的炎症,为开发抑制幽门螺杆菌的食品(例如膳食补充剂、保健品)、药物等产品提供了菌种资源。
动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)具有以下微生物学特性:
(1)形态学特征
革兰染色呈阳性,光镜下为直杆或弯曲短杆,单个或成对排列,V型或弯曲状;在MRS固体培养基上形成菌落,菌落光滑,凸圆,边缘完整,呈乳白色,闪光并有柔软质地。
(2)生理特性
动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)能在人工胃酸条件下生长良好,并能在体外培养实验中抑制幽门螺杆菌的生长,抑菌环直径达18.0mm,在动物实验中能抑制幽门螺杆菌在体内的定植并缓解致病菌感染所造成的炎症。
动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)可采用以下方法进行培养:将动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)接种于培养基中,35-37℃厌氧培养,培养时间可为12-24h。所述培养基可以采用本领域常规的培养基,能够使得动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)生长即可,优选采用MRS肉汤培养基(酪蛋白酶消化物10.0g/L,牛肉膏粉10.0g/L,酵母膏粉4.0g/L,柠檬酸三铵2.0g/L,乙酸钠5.0g/L,七水硫酸镁0.2g/L,四水硫酸锰0.05g/L,葡萄糖20.0g/L,磷酸氢二钾2.0g/L,吐温80 1.0g/L,pH=5.7±0.2),固体培养基加入1.5%琼脂。
经安全性评估,按GB 15193.3-2014相关规定进行急性经口毒性实验,结果表明小鼠行为和精神状况良好,动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)属于实际无毒级别;依据《食品安全国家标准食品用菌种安全性评价程序(征求意见稿)》相关规定,对动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)全基因组测序后,将全基因组序列同CARD、ResFinder、Argannot、NDARO的最新版本中存储的序列进行比对,结合抗生素耐药性测试实验,结果证明该菌株不含可转移的抗生素抗性基因;将全基因组序列同VFDB、PAIDB、MvirDB、CGE数据库中最新序列进行了比对,结果表明该菌株不含毒力因子。
本发明提供一种微生物制剂,所述微生物制剂包含动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)。
优选地,以上所述的微生物制剂中,动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)以活菌形式存在。
以上所述的微生物制剂可为固体制剂(例如菌粉)或液体制剂(例如乳液制剂)。
本发明提供以上所述的微生物制剂的制备方法,所述方法包括培养所述动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)的步骤。
优选地,所述培养为在35-37℃条件下厌氧培养。
优选地,所述培养为在液体培养基中厌氧培养,获得菌液。
上述菌液可直接或者经浓缩和/或加入其他辅料制备为液体制剂,或者经干燥制备为固体制剂,或者将菌液中的菌体进行分离再将菌体制备为固体制剂。
基于动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)的功能,本发明提供该菌株的以下应用:
本发明提供动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)或所述微生物制剂在制备用于抑制幽门螺杆菌的产品中的应用。
本发明提供动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)或所述微生物制剂在抑制幽门螺杆菌中的应用。
其中,抑制幽门螺杆菌包括在体外抑制幽门螺杆菌的生长,或者在体内抑制幽门螺杆菌的定植、感染、增殖、生长。
本发明提供动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)或所述微生物制剂在制备用于预防、缓解或治疗幽门螺杆菌感染或由幽门螺杆菌感染导致疾病的产品中的应用。
其中,由幽门螺杆菌感染导致疾病优选为胃肠道疾病,包括胃炎、胃溃疡、十二指肠溃疡、胃癌等。
本发明提供动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)或所述微生物制剂在制备用于预防、缓解或治疗幽门螺杆菌感染导致的炎症的产品中的应用。
其中,幽门螺杆菌感染导致的炎症包括胃粘膜组织炎症、十二指肠炎症等。
以上所述的产品包括食品、饲料或药物。
本发明提供动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)或所述微生物制剂在制备食品、饲料或药物中的应用。
本发明中,食品包括普通食品、膳食补充剂、保健品。
本发明提供一种食品,所述食品包含动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)或所述微生物制剂。
除包含动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)或所述微生物制剂外,所述食品还可包含食品领域允许的原料。所述食品可为膳食补充剂、保健品或发酵食品。
本发明提供一种药物,所述药物包含动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)或所述微生物制剂。
除包含动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)或所述微生物制剂外,所述药物还可包含药学领域允许的辅料(例如填充剂、赋型剂、润滑剂、润湿剂、稀释剂等)。药物的制剂类型可为固体制剂(例如粉剂、颗粒剂、胶囊剂、片剂等)或液体制剂(例如口服液等)。
本发明的有益效果至少包括:本发明提供的动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)在胃酸存在环境下生长良好,具有较好的耐酸能力,可很好地适应于胃部环境;该菌株对幽门螺杆菌具有明显的生长抑制作用,在动物实验中能够抑制幽门螺杆菌在体内的定植、降低幽门螺杆菌载量,并缓解幽门螺杆菌感染所造成的炎症,从而可起到调节消化道微生物菌群的作用。
动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)可用于制备用于预防、缓解或治疗幽门螺杆菌感染或其导致疾病的产品,在临床预防、治疗和抑制幽门螺杆菌感染相关病症以及胃肠道保健食品等领域具有广阔的应用前景。
附图说明
为了更清楚地说明本发明或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作一简单地介绍,显而易见地,下面描述中的附图是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1为实施例1中动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)在MRS培养基上的菌落形态图。
图2为实施例1中动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)镜检图。
图3为实施例2中动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)在人工胃酸和PBS对照条件下生长2h后存活率比较,其中数据来自三次重复实验,误差线表示标准差,其中ns表示无显著性差异。
图4为实施例3中动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)体外抑菌圈直径大小,其中数据来自两次重复实验,误差线表示标准差;统计分析方法为Student's t-test,**表示p值小于0.01。
图5为实施例4中不同组别胃组织硝酸银染色结果图,其中,A:空白组,B:Hp感染组,C:抗生素药物组,D:益生菌组。
图6为实施例5中不同组别胃组织苏木精-伊红染色结果图,其中,A:空白组,B:Hp感染组,C:抗生素药物组,D:益生菌组。
图7为实施例6中不同组别胃粘膜组织尿素酶检测结果图,其中,A:空白组,B:Hp感染组,C:抗生素药物组,D:益生菌组。
图8为实施例7中不同组别胃粘膜组织促炎细胞因子白介素-6(IL-6,A)和促炎细胞因子白介素-8(IL-8,B)含量测定结果图,其中,相对蛋白浓度是各组蛋白浓度相对于空白组蛋白浓度归一化后的相对值;误差线表示标准差;统计分析方法为单因素方差分析(One-Way ANOVA),*表示p值小于0.05,**表示p值小于0.01,ns表示无显著性差异。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚,下面将结合本发明中的附图,对本发明中的技术方案进行清楚、完整地描述,显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
以下实施例中所用的幽门螺杆菌菌株为Helicobacter pylori NCTC11639,受赠于南昌大学第一附属医院消化***疾病研究所。
实施例1动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)的分离及鉴定
1、动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)的分离
1.1样品来源
本发明所使用的动物双歧杆菌乳亚种(Bifidobacterium animalissubsp.lactis)菌株分离自健康婴儿粪便。
1.2培养基的配制
样品分离和菌株筛选所用的培养基为MRS固体培养基,MRS培养基成分如下:酪蛋白酶消化物10.0g/L,牛肉膏粉10.0g/L,酵母膏粉4.0g/L,柠檬酸三铵2.0g/L,乙酸钠5.0g/L,七水硫酸镁0.2g/L,四水硫酸锰0.05g/L,葡萄糖20.0g/L,磷酸氢二钾2.0g/L,吐温801.0g/L,pH=5.7±0.2,加入1.5%琼脂即为MRS固体培养基。
1.3菌株的分离
将1g粪便样品放入10mL步骤1.2制得的MRS液体培养基中,混匀后于36℃下培养,然后在超净台中吸取富集液1mL,进行10倍梯度稀释,选取10-5、10-6、10-7三个稀释梯度的菌液100μL涂于含有无菌MRS固体培养基的培养皿上,于有氧条件下36℃静置培养24-48h,至有明显单菌落形成后,从培养基中选择生长有70-120个单菌落的平板,挑取典型菌落,在MRS固体平板培养基上多次划线纯化,直至整个平板上的菌落形态一致的培养物做菌株鉴定。
2、动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)的鉴定
2.1菌落特征
动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)在MRS固体培养基中培养24h后,菌落呈光滑,凸圆,边缘完整,呈乳白色,闪光并有柔软质地,见图1。
2.2显微镜下形态
动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)菌落涂片:革兰染色呈阳性,光镜下为直杆或弯曲短杆,单个或成对排列,V型或弯曲状。见图2。
2.3 16S rDNA鉴定
鉴定单位:擎科生物科技有限公司。
鉴定序列:16S rDNA序列如SEQ ID NO.1所示。
鉴定结果:根据菌株的序列比对结果和生理生化结果相结合,确定该菌株为动物双歧杆菌乳亚种(Bifidobacterium animalis subsp.lactis)。
实施例2动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)耐胃酸能力检测
人体胃环境中整体pH条件呈强酸性,因此,菌株的耐酸能力是评估其是否能在胃酸环境下存活、定植的重要指标。使用人工胃液模拟胃部环境,胃酸消化组中,向含有100μL动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)菌液的96孔板中加入100μL模拟人工胃液,吹打混匀,37℃,厌氧共孵育2h;对照组中,向含有100μL动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)菌液的96孔板中加入100μL PBS,吹打混匀,37℃,厌氧共孵育2h,孵育结束后取出孔板。
取胃酸消化组孵育样品,用PBS稀释到10E-5;取对照组孵育样品,用PBS稀释到10E-6。将稀释后样品涂布在MRS琼脂平板上,于37℃厌氧培养16h后进行菌落计数,并计算菌体存活率,计算公式为:存活率/%=(胃酸消化组活菌数logCFU/mL/对照组活菌数logCFU/mL)×100%。
经胃酸消化2小时后,动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)存活率为121%(图3),与PBS对照组相比没有显著性差异,表明该菌株耐酸能力强,能够在胃部环境中存活、定植。
实施例3动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)体外抑菌性能检测
1、菌株培养
幽门螺杆菌Helicobacter pylori NCTC11639(以下简称H.pylori)经血平板培养基复苏后接种于BD液体培养基,37℃微需氧条件培养48h;动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)经MRS固体培养基活化后接种于MRS液体培养基,37℃培养24h。
微需氧条件是指氧气浓度5%(体积百分含量)、二氧化碳浓度10%(体积百分含量)的环境。
2、抑菌试验
采用打孔法进行抑菌试验,将动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)过夜培养菌液于6000rpm离心10分钟后取上清,经0.22μm滤头除菌后得到菌株发酵上清液。在MH固体培养基上涂布幽门螺杆菌至10E9 CFU,待平板干涸后用打孔器打孔,向孔中加入菌株发酵上清液,以PBS作为阴性对照。37℃微需氧孵箱中培养血平板48h,测量抑菌圈直径。与PBS对照组相比,动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)发酵上清液显著增加了抑菌圈直径(图4),表现出明显的体外抑制幽门螺杆菌的效果。
实施例4沙鼠模型中动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)抑制幽门螺杆菌效果检测
分组:36只蒙古沙鼠,雄性,6-8周龄,适应喂养一周后随机分为4组,分别为空白组(6只)、Hp感染组(只灌胃H.pylori,12只)、抗生素药物组(先灌胃H.pylori后灌胃铋剂四联,6只)、益生菌组(先灌胃H.pylori后灌胃动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18),12只)。
造模:待造模沙鼠禁食不禁水24h后,使用小鼠灌胃针进行108CFU幽门螺杆菌菌液的灌胃处理,灌胃处理持续10日。
干预:确认造模成功后开始进行抗生素药物和益生菌饲喂。抗生素药物组沙鼠,使用铋剂四联;益生菌组沙鼠,使用小鼠灌胃针进行108CFU益生菌的灌胃处理,持续21天。益生菌选择处于生长对数期的生长旺盛的菌液。Hp感染组沙鼠和空白组沙鼠,同样使用小鼠灌胃针进行生理盐水的灌胃处理,持续21天。
干预21天后处死小鼠,取胃部组织,用10%***固定,经石蜡切片后,进行Warthin-Starry硝酸银染色。螺旋体表面的粘蛋白会特异性的与银结合,呈黑色。Hp感染组胃组织硝酸银染色图中可看到黑色短棒状颗粒及菌丝,被染色程度最严重,面积最大。抗生素治疗可以改变感染情况,动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)可以轻微改善被感染情况(图5)。
实施例5沙鼠模型中胃组织病理学分析
取实施例4中灌胃后四组实验沙鼠的胃组织切片,进行苏木精-伊红染色。结果见图6。图片均显示了前胃和后胃,前胃主要为鳞状上皮,后胃为柱状上皮。胃壁主要包括黏膜层、黏膜下层、肌层和浆膜层,各层组织结构正常。在空白组中,未见黏膜上皮细胞变性、坏死,固有层、黏膜下层未见炎细胞浸润;Hp感染组中黏膜上皮细胞轻度变性、坏死,固有层、黏膜下层少见炎细胞浸润;而在抗生素药物组和益生菌组中,黏膜上皮细胞轻微变性、坏死,固有层、黏膜下层轻微炎细胞浸润。病理组织评分见表1。以上结果表明,与抗生素类似,动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)干预减轻了幽门螺杆菌感染造成的胃组织病变和炎症。
表1实施例5中不同组别胃组织病理组织评分表
实施例6沙鼠模型中胃粘膜组织尿素酶分析
Hp在胃内可以产生大量尿素酶,因此可通过检测尿素酶来判断Hp感染。尿素酶黄色试纸的最终颜色为黄色则视为阴性,为玫瑰色或者浅红色则视为阳性。取实施例4灌胃后四组实验沙鼠的胃组织粘膜,用牙签取组织放在尿素酶黄色试纸中央,然后将不干胶覆合在塑料胶片上,使不干胶与塑料胶片紧密结合,1-3分钟观察试纸颜色变化,见图7。抗生素药物组与空白组HP未显示为阳性,Hp感染组与益生菌组的HP结果为阳性,但益生菌组与感染组相比,试纸颜色明显偏黄,这表明动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)干预可以明显降低幽门螺杆菌载量。
实施例7沙鼠模型中胃粘膜组织炎症分析
取实施例4灌胃后四组实验沙鼠的胃组织粘膜,加入RIPA裂解液后充分匀浆,提取组织中的蛋白质。采用BCA试剂盒测定总蛋白含量。使用酶联免疫吸附试剂盒测定促炎细胞因子白介素-6(IL-6)和促炎细胞因子白介素-8(IL-8)的含量。从图8可以看出,与感染组相比,益生菌处理显著降低了IL-6和IL-8蛋白水平,且益生菌组的IL-6和IL-8蛋白水平显著低于抗生素药物组,这表明动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)能够减轻幽门螺杆菌感染造成的胃组织炎症反应,其效果优于常用于幽门螺杆菌感染治疗的抗生素。
综上所述,本发明通过分离筛选获得了一株动物双歧杆菌乳亚种,命名为动物双歧杆菌乳亚种ATM-209(GOLDGUT-BB18)。对该株动物双歧杆菌乳亚种进行体外耐酸、抑制幽门螺杆菌生长的实验,证明该株动物双歧杆菌乳亚种对胃环境具有强耐受性且具有抑制幽门螺杆菌生长的效果。进一步通过蒙古沙鼠模型发现该株动物双歧杆菌乳亚种能够有效降低幽门螺杆菌的体内生长以及缓解由幽门螺杆菌感染所造成的胃组织炎症。由此表明,该菌株适于消化道环境,且具有优异的对抗幽门螺杆菌的能力,在对抗胃肠道致病菌幽门螺杆菌方面具有广阔的应用前景。
最后应说明的是:以上实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的精神和范围。
Claims (10)
1.动物双歧杆菌乳亚种(Bifidobacterium animalis subsp.lactis)ATM-209,其特征在于,其保藏于中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为CGMCCNo.25896。
2.一种微生物制剂,其特征在于,所述微生物制剂包含权利要求1所述的动物双歧杆菌乳亚种(Bifidobacterium animalis subsp.lactis)ATM-209。
3.权利要求2所述的微生物制剂的制备方法,其特征在于,所述方法包括培养所述动物双歧杆菌乳亚种(Bifidobacterium animalis subsp.lactis)ATM-209的步骤。
4.根据权利要求3所述的方法,其特征在于,所述培养为在35-37℃条件下厌氧培养。
5.权利要求1所述的动物双歧杆菌乳亚种(Bifidobacterium animalissubsp.lactis)ATM-209或权利要求2所述的微生物制剂在制备用于抑制幽门螺杆菌的产品中的应用。
6.权利要求1所述的动物双歧杆菌乳亚种(Bifidobacterium animalissubsp.lactis)ATM-209或权利要求2所述的微生物制剂在制备用于预防、缓解或治疗幽门螺杆菌感染或由幽门螺杆菌感染导致疾病的产品中的应用。
7.权利要求1所述的动物双歧杆菌乳亚种(Bifidobacterium animalissubsp.lactis)ATM-209或权利要求2所述的微生物制剂在制备用于预防、缓解或治疗幽门螺杆菌感染导致炎症的产品中的应用。
8.权利要求1所述的动物双歧杆菌乳亚种(Bifidobacterium animalissubsp.lactis)ATM-209或权利要求2所述的微生物制剂在制备食品、饲料或药物中的应用。
9.一种食品,其特征在于,所述食品包含权利要求1所述的动物双歧杆菌乳亚种(Bifidobacterium animalis subsp.lactis)ATM-209或权利要求2所述的微生物制剂。
10.一种药物,其特征在于,所述药物包含权利要求1所述的动物双歧杆菌乳亚种(Bifidobacterium animalis subsp.lactis)ATM-209或权利要求2所述的微生物制剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310578935.7A CN116622572A (zh) | 2023-05-22 | 2023-05-22 | 抑制幽门螺杆菌的动物双歧杆菌乳亚种atm-209及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310578935.7A CN116622572A (zh) | 2023-05-22 | 2023-05-22 | 抑制幽门螺杆菌的动物双歧杆菌乳亚种atm-209及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116622572A true CN116622572A (zh) | 2023-08-22 |
Family
ID=87620741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310578935.7A Pending CN116622572A (zh) | 2023-05-22 | 2023-05-22 | 抑制幽门螺杆菌的动物双歧杆菌乳亚种atm-209及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116622572A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170062330A (ko) * | 2015-11-27 | 2017-06-07 | 제이나인바이오 영농조합법인 | 헬리코박터 파이로리의 위점막 부착 억제능력을 가지는 조성물, 그 제조방법 및 이를 활용한 기능성 음료. |
CN111575214A (zh) * | 2020-06-02 | 2020-08-25 | 北京科拓恒通生物技术股份有限公司 | 一株具有抗幽门螺杆菌功能的乳双歧杆菌及其应用 |
CN115119940A (zh) * | 2021-12-23 | 2022-09-30 | 微康益生菌(苏州)股份有限公司 | 嗜酸乳杆菌LA85和乳双歧杆菌BLa80在抑制幽门螺旋杆菌上的应用 |
-
2023
- 2023-05-22 CN CN202310578935.7A patent/CN116622572A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170062330A (ko) * | 2015-11-27 | 2017-06-07 | 제이나인바이오 영농조합법인 | 헬리코박터 파이로리의 위점막 부착 억제능력을 가지는 조성물, 그 제조방법 및 이를 활용한 기능성 음료. |
CN111575214A (zh) * | 2020-06-02 | 2020-08-25 | 北京科拓恒通生物技术股份有限公司 | 一株具有抗幽门螺杆菌功能的乳双歧杆菌及其应用 |
CN115119940A (zh) * | 2021-12-23 | 2022-09-30 | 微康益生菌(苏州)股份有限公司 | 嗜酸乳杆菌LA85和乳双歧杆菌BLa80在抑制幽门螺旋杆菌上的应用 |
Non-Patent Citations (1)
Title |
---|
游宇, 等: "抗幽门螺杆菌的胃原籍益生菌株的筛选", 江西医药, vol. 47, no. 06, 20 June 2012 (2012-06-20), pages 471 - 473 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108004189A (zh) | 一种复合益生乳酸菌粉剂及其制备方法与应用 | |
CN105062933A (zh) | 一种罗伊氏乳杆菌及其应用 | |
CN105543126A (zh) | 一种植物乳杆菌jm113及其应用 | |
CN113337431B (zh) | 一株抑制幽门螺杆菌的罗伊氏乳杆菌nsl0501及其生物菌剂和应用 | |
CN104805040B (zh) | 一种枯草芽孢杆菌制剂及制备方法和应用 | |
CN111011856A (zh) | 用于缓解胃病的组合物、其制备方法及用于缓解胃病的食品 | |
CN110564638A (zh) | 一株具有益生特性的罗伊氏乳杆菌及其用途 | |
CN112625979B (zh) | 一种对抗幽门螺杆菌的干酪乳杆菌及其应用 | |
CN1273838A (zh) | 含有死的益生菌共生发酵培养物的营养组合物 | |
CN111548972A (zh) | 一株具有抗幽门螺旋杆菌功能的植物乳杆菌及其应用 | |
CN111996153A (zh) | 一种短双歧杆菌及其应用 | |
CN113122466A (zh) | 粪肠球菌及其应用 | |
CN117568211A (zh) | 一株具有抗沙门氏菌感染功能的植物乳植杆菌goldgut-lp618及其应用 | |
CN109486732B (zh) | 一种长双歧杆菌及其应用 | |
CN113088468B (zh) | 干酪乳杆菌Ma.GLRGJ 1及其应用 | |
CN115029260A (zh) | 一种具有抗炎及抗氧化特性的格氏乳杆菌及应用 | |
CN112239739B (zh) | 一株可缓解etec致腹泻的植物乳杆菌及其应用 | |
CN117143767B (zh) | 可调节肠道菌群的母乳源发酵粘液乳杆菌msjk0025及其应用 | |
CN112029676B (zh) | 一种有利于提高免疫力的益生菌组合及其应用 | |
CN114703107B (zh) | 一株副干酪乳酪杆菌及其在预防婴幼儿链球菌感染中的应用 | |
CN112980737B (zh) | 一株促进动物双歧杆菌增殖的青春双歧杆菌及其应用 | |
TW201016847A (en) | A strain of Lactobacillus plantarum and its use for inhibiting Helicobacter pylori growth | |
CN116622572A (zh) | 抑制幽门螺杆菌的动物双歧杆菌乳亚种atm-209及其应用 | |
KR20050023475A (ko) | 돼지 유행성 설사증 (PED) 코로나바이러스 및 유해 미생물억제 활성을 가지는 신규 내 산성 엔테로코커스 훼카리스Probio-056 및 이를 함유하는 생균활성제 | |
CN116790402B (zh) | 一株具有抗炎特性的单形拟杆菌菌株、培养方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |